Sign inJoin waitlistJoin the waitlist

AC

Adam Crystal

President, Research & Dev’t, Tango Therapeutics · University of Pennsylvania Health System

Credentials: · · ·

History

Research & Dev’t · University of Pennsylvania Health System
Present

Medical Oncology
2009–2011
Internal Medicine
2006–2009
Perelman School of Medicine at the University of Pennsylvania
2002–2006

Research

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Nature Medicine · 2016 · 810 citations
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Review · Nature reviews. Cancer · 2017 · 745 citations
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
Cancer Discovery · 2014 · 678 citations

Robert Doms
5 papers
Alice Shaw
4 papers
JE
Jeffrey Engelman
4 papers
DR
Danielle Roselin
3 papers
Deborah Blacker
3 papers
Elizabeth Lockerman
3 papers
RF
Ryan Fortna
3 papers · 1 as a resident
Anthony Iafrate
2 papers
Bradley Hyman
2 papers
Jerrilyn Jones
2 papers
JG
Justin Gainor
2 papers · 2 as a fellow
Lecia Sequist
2 papers

Clinical trials

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Study director · Terminated · Phase 1, Phase 2
Tango Therapeutics, Inc.
2023–2024
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Study director · Active not recruiting · Phase 1, Phase 2
Tango Therapeutics, Inc.
2023–2026